About FDA

Innovation: Speeches and Testimony

U.S. Food and Drug Administration officials have traveled the nation—and the world—to share updates on our accomplishments and work to encourage new advances. We also remain dedicated to assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our food supply, cosmetics, and products that emit radiation.

See what our staff have said about our forward-looking activities. 

Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research“Probably the most exciting accomplishment since the enactment of the [Biologics Price Competition and Innovation Act of 2009] is FDA’s approval of the first biosimilar in the United States. On March 6, 2015, FDA approved the first biosimilar, Zarxio (filgrastim-sndz), a biosimilar to Neupogen (filgrastim), a reference product licensed by FDA that is used to help stimulate growth of white blood cells in patients with cancer and help them fight infection."
—Janet Woodcock, M.D., Director of the FDA's Center for Drug Evaluation and Research

Learn more by reading Dr. Woodcock's testimony, Biosimilar Implementation: A Progress Report from FDA. 


Biologic and Drug Development

Other Topics and General Overviews

Page Last Updated: 12/21/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English